Raymond James Financial’s Opus Genetics IRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$82.3K Buy
16,997
+1,989
+13% +$8.26K ﹤0.01% 5246
2026
Q2
$61.7K Sell
15,008
-4,500
-23% -$21K ﹤0.01% 5234
2026
Q1
$88.8K Sell
19,508
-1,000
-5% -$3.46K ﹤0.01% 5060
2025
Q4
$41.2K Sell
20,508
-2,000
-9% -$4.06K ﹤0.01% 5028
2025
Q3
$37.1K Buy
22,508
+11,000
+96% +$13.7K ﹤0.01% 4854
2025
Q2
$10.8K Hold
11,508
– – ﹤0.01% 5893
2025
Q1
$11.3K Sell
11,508
-3,472
-23% -$3.88K ﹤0.01% 4769
2024
Q4
$17.8K Buy
+14,980
New +$17.2K ﹤0.01% 4734

Other funds holding IRD

Raymond James Financial's IRD Position: Q3 2026 in Review

Raymond James Financial increased its Opus Genetics (IRD) stake by 13% in Q3 2026, buying an estimated $8.26K and bringing the position to 16,997 shares worth $82.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5246.

Raymond James Financial first reported a position in IRD in Q4 2024 and has held it in 8 quarters since. The position peaked at $88.8K in Q1 2026. 112 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • Raymond James Financial held 16,997 shares of Opus Genetics worth $82.3K as of Q3 2026.
  • Raymond James Financial bought 1,989 Opus Genetics shares in Q3 2026, an estimated $8.26K.
  • Opus Genetics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5246 holding.
  • Raymond James Financial first reported a position in Opus Genetics in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's Opus Genetics position peaked at $88.8K in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.